Nasus Pharma (NSRX) Payables (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Payables came in at $829000.0 in Q4 2025, up 27.34% YoY from $651000.0 in Q4 2024, and up 24.85% on a QoQ basis from $664000.0 in Q2 2025.
Nasus Pharma (NSRX) Payables (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Payables data on file, last reported at $829000.0 in Q4 2025.
- Quarterly Payables rose 27.34% year-over-year to $829000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $829000.0 (up 27.34% YoY) and the FY2025 annual result came in at $829000.0, up 27.34% from the prior year.
- Payables climbed to $829000.0 in Q4 2025, from $664000.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $829000.0 in Q4 2025 to a low of $651000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.63 Bn | 632.88 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 471.61 Bn | 465.04 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 380.82 Bn | 373.68 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 303.41 Bn | 295.72 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 258.06 Bn | 253.16 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.46 Bn | 223.47 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 161.82 Bn | 150.12 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.95 Bn | 101.79 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Nasus Pharma | 29.73 Mn | 29.73 Mn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 829,000.00 |
| Jun 30, 2025 | 664,000.00 |
| Dec 31, 2024 | 651,000.00 |